These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8309960)

  • 1. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
    Paronis CA; Waddell AB; Holtzman SG
    Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro.
    Feng J; Kendig JJ
    Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay.
    Wettstein JG; Grouhel A
    Pharmacol Biochem Behav; 1996 Feb; 53(2):411-6. PubMed ID: 8808151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.
    Broadbear JH; Negus SS; Butelman ER; de Costa BR; Woods JH
    Psychopharmacology (Berl); 1994 Jul; 115(3):311-9. PubMed ID: 7871070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of morphine-like discriminative effects by beta-funaltrexamine.
    Holtzman SG
    Pharmacol Biochem Behav; 1997 Aug; 57(4):771-7. PubMed ID: 9259005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats.
    Takemori AE; Schwartz MM; Portoghese PS
    J Pharmacol Exp Ther; 1988 Dec; 247(3):971-4. PubMed ID: 2849679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors.
    Reche I; Fuentes JA; Ruiz-Gayo M
    Eur J Pharmacol; 1996 Dec; 318(1):11-6. PubMed ID: 9007506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine.
    Rauhut AS; Gehrke BJ; Phillips SB; Bardo MT
    Pharmacol Biochem Behav; 2002 Oct; 73(3):611-22. PubMed ID: 12151036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term kappa-opioid receptor blockade following nor-binaltorphimine.
    Jones DN; Holtzman SG
    Eur J Pharmacol; 1992 May; 215(2-3):345-8. PubMed ID: 1327807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
    Adams JU; Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice.
    Narita M; Suzuki T; Misawa M; Nagase H
    Psychopharmacology (Berl); 1993; 110(1-2):254-6. PubMed ID: 7870894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
    Takemori AE; Portoghese PS
    J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions.
    Bodnar RJ; Glass MJ; Ragnauth A; Cooper ML
    Brain Res; 1995 Nov; 700(1-2):205-12. PubMed ID: 8624711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats.
    Craft RM; McNiel DM
    Pharmacol Biochem Behav; 2003 Apr; 75(1):235-45. PubMed ID: 12759132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
    Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further characterization of the discriminative stimulus effects of spiradoline.
    Holtzman SG
    Pharmacol Biochem Behav; 2000 Jul; 66(3):517-22. PubMed ID: 10899364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
    Steinmiller CL; Young AM
    Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes.
    Spanagel R; Almeida OF; Shippenberg TS
    Eur J Pharmacol; 1994 Oct; 264(2):157-62. PubMed ID: 7851478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential involvement of opioid receptors in intrathecal butorphanol-induced analgesia: compared to morphine.
    Wongchanapai W; Tsang BK; He Z; Ho IK
    Pharmacol Biochem Behav; 1998 Mar; 59(3):723-7. PubMed ID: 9512078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.